Actimed Therapeutics

Feb 02, 2021

Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer

Dec 01, 2020

Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM-002 (S-oxprenolol) for Treating Cancer Cachexia

Nov 23, 2020

Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité - Universitätsmedizin Berlin

Sep 02, 2020

Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China

Apr 02, 2020

Actimed Therapeutics Appoints Annalisa Jenkins as Advisor